Study on effect of vascular endothelial growth factor on acute myeloid leukemic cells in vitro

WANG Yi,XIAO Zhi-jian,LIU Peng,JIANG Wen-qi,LIU Zong-chao,HAN Zhong-chao
DOI: https://doi.org/10.3969/j.issn.1673-5269.2006.14.016
2006-01-01
Abstract:OBJECTIVE:To investigate the effect of vascular endothelial growth factor (VEGF) on acute myeloid leukemic cells.METHODS: Cell proliferation was detected by the trypan blue exclusion assay, the apoptosis and concentration of intracellular bcl-2 protein by flow cytometry, and the number of cells colonies by the colony-forming assay. RESULTS: The living cells number in VEGF group, which was (3.63±1.27)×10~6 mL~ -1 was not significantly different from the negative controls (3.23±1.60)×10~6 mL~ -1 . The protein level of intracellular bcl-2 in leukaemic cells group (70.78±13.36)% was muchs higher than that in the normal controls (18.55±9.24)%, P=0.039; so was the intracellular bcl-2-incubation with VEGF (50.85±30.46)% compared with the controls (36.52±12.38)%. The percentage of apoptotic cells induced by Ara-C was much more than that in leukemic cells incubated with VEGF group. The number of non-erythroid colonies (49.9±29.2)/0.5 mL, with VEGF was much more than that of the control (36.5±12.4)/0.5 mL, P=0.013. VEGF did not up regulate the number of mix-colonies, but VEGF promoted the proliferation of AML stem/progenitor cells. CONCLUSIONS: VEGF can resist leukemic cell apoptosis induced by Ara-C and promote leukemic stem/progenitor cells. Therefore, VEGF, as a novel thorapeutic target, can improve therapy outcome in AML.
What problem does this paper attempt to address?